



Publikationen

2014

- Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M. A "PSA Pyramid" for Men with Initial Prostate-specific Antigen ≥ 3 ng/ml: A Plea for Individualized Prostate Cancer Screening. *Eur Urol*. 2014 Apr 18. [Epub ahead of print]
- Zappa M, Puliti D, Hugosson J, Schröder FH, van Leeuwen PJ, Kranse R, Auvinen A, Carlsson S, Kwiatkowski M, Nelen V, Borda AP, Roobol MJ, Villers A. A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality. *Eur Urol*. 2014 Jan 7. [Epub ahead of print]
- Becker A, Seiler D, Kwiatkowski M, Kluth LA, Schnell D, Graefen M, Schlomm T, Fisch M, Recker F, Weissbach L, Chun FK. A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. *World J Urol*. 2014 May 13. [Epub ahead of print]
- Kleist C, Randazzo M, Jiga J, Terness P. Heat shock proteins purified from autologous tumors using antibody-based affinity chromatography. *Methods Mol Biol*. 2014;1139:305-19. doi: 10.1007/978-1-4939-0345-0_25.

2013

- Recker F, Seiler D, Seifert B, Randazzo M, Kwiatkowski M. [PSA screening 2013: Background and perspectives.] *Urologe A*. 2013 May 29
- Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE. Bacillus Calmette-Guérin Failure in Patients with Non-Muscle-invasive Urothelial Carcinoma of the Bladder May Be Due to the Urologist's Failure to Detect Urothelial Carcinoma of the Upper Urinary Tract and Urethra. *Eur Urol*. 2013 Oct 9
- Strebel RT, Schmidt C, Beatrice J, Sulser T. Chronic scrotal pain syndrome (CSPS): the widespread use of antibiotics is not justified. *Andrology*. 2013 Jan;1(1):155-9.
- Becker A, Placke AK, Kluth LA, Schwarz R, Isbarn H, Chun FK, Heuer R, Schlomm T, Seiler D, Engel O, Fisch M, Graefen M, Ahyai SA. Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms - a retrospective feasibility study. *J Endourol*. 2013 Oct 22
- Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi



- F, Shariat SF, Briganti A. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. *Eur Urol.* 2013 Jul 2
- Seiler D, Zheng J, Liu G, Wang S, Yamashiro J, Reiter RE, Huang J, Zeng G. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. *Prostate.* 2013 Sep;73(13):1378-90.
 - [Müller A, Bitton A, Vaucher L, Eijsten A, Beatrice J. Erektile Dysfunktion: wie weiter? Praktische Empfehlungen aus Sicht des Urologen. 2013](#)
 - Kwiatkowski M, Huber A. Das PSA im Fokus. *Der Informierte Arzt* 2013(12);34
 - Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V & Panel Members. Prostate cancer: ESMO Consensus Conference Guidelines 2012. *Annals of Oncology* 2013;1-22

2012

- Olkhov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner NE, Diamandis EP, Zlotta AR, Bapat B. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. *Epigenetics.* 2012 Sep;7(9):1037-45
- Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V & Panel Members. Prostate cancer: ESMO Consensus Conference Guidelines 2012. *Annals of Oncology* 2013;1-22
- Schröder FH, Hugosson J, Carlsson S, Tammela T, Mänttinen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). *Eur Urol.* 2012;62:745-52
- Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ. Quality-of-life effects of prostate-specific antigen screening. *N Engl J Med.* 2012 Aug 16;367(7):595-605.
- Randazzo M, Kwiatkowski M, Recker F. PSA und Prostatakrebsfrüherkennung. *Schweizerische Zeitschrift für Onkologie* 3/ 2012.
- Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F and Kwiatkowski M. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. *BJU Int.* 2012;110:195-200
- Randazzo M, Terness P, Opelz G, Kleist C. Active specific immunotherapy of human cancers with the heat shock protein Gp96 –revisited. *Int J Cancer.* 2012 May



15;130(10):2219-31

- Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Mänttinen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ and Auvinen A. Prostate-cancer mortality at 11 years of follow-up. *N Engl J Med.* 2012 Mar 15;366(11):981-90
- Seiler D, Randazzo M, Leupold U, Zeh N, Isbarn H, Chun FK, Ahyai SA, Baumgartner M, Huber A, Recker F, Kwiatkowski M. Protocol-based Active Surveillance for Low-risk Prostate Cancer: Anxiety Levels in Both Men and Their Partners. *Urology.* 2012 Sep;80(3):564-9
- Kwiatkowski M, Klotz L, Hugosson J, Recker F. Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer. *Eur Urol.* 2012;61:851-4
- Randazzo M, Recker F. Feinere Filter – bessere Behandlung. *VSAO Journal* 2012, April; 2: 40-43
- Recker F. „U.S. Preventive Services Task Force Recommendation“ oder „Das Kind mit dem Bade ausschütten“. *Urologe* 2012;51:74-76

2011

- Cathomas R, Berthold D, Gillessen S, Recker F, Stenner F, Strebel R, Sulser T, Zwahlen DR, Schmid H-P. Das Prostatakarzinom im Wandel; Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität. *Schweiz Med Forum* 2011;11(43):759-763
- Recker F, Sulser T. Messung des prostataspezifischen Antigens (PSA-Test) zur Früherkennung des Prostatakarzinoms; Swiss Medical Board oder: "Das Kind mit dem Bade ausschütten". *Schweizerische Ärztezeitung* 2011; 92:51/52
- Randazzo M, Seiler D, Recker F, Kwiatkowski M. PSA-Screening in der Prostatakarzinomvorsorge – Versuch einer kritischen Analyse. *Hausarzt Praxis* 2011 September; 11-14

2010

- Möltgen T, Gräfe K, Seiler D, Recker F, Kwiatkowski M. Prostata-Karzinom-Screening: Wo stehen wir nach den Kontroversen? *Hausarzt Praxis* 2/10
- Kwiatkowski M, Recker F, Huber A, Sergeeva NA, Brinkmann T. Standardization of the laboratory test for PSA. *Urologia* 2010;(4):64, 66-7



- Boevee SJ, Venderbos LD, Tammela TL, Nelen V, Ciatto S, Kwiatkowski M, Paez A, Malavaud B, Hugosson J, Roobol MJ. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. *Eur J Cancer* 2010;46:3082-9
- Otto SJ, Moss SM, Maattanen L, Roobol M, Zappa M, Nelen V, Kwiatkowski M, Villers A, Hugosson J, Sanchez AB, de Koning HJ. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. *Eur J Cancer* 2010;46:3053-60
- Recker F. Vertiefte Analyse zweier Studien zum Prostatakarzinom-Screening – Was macht Sinn? *Praxis* 2010;99: 183-185

2009

- Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, Ciatto S, Kwiatkowski M, Villers A, Lujan M, Nelen V, Tammela TL, Schroder FH. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. *International Journal of Cancer* 2009;126:2387-93
- Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). *European Urology* 2009;56:584-91
- Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study. *The New England Journal of Medicine* 2009;360:1320-8

2008

- Kwiatkowski M, Stieber P, Huber AR, Recker F. [Selective application of tumor markers PSA]. *Therapeutische Umschau*. 2008;65:493-501
- Arndt B, Kwiatkowski M, Recker F. [Status of care for prostate cancer in 2008]. *Der Urologe* 2008;47:969-74



2006

- Stephan C, Meyer HA, Kwiatkowski M, Recker F, Cammann H, Loening SA, Jung K, Lein M. A (-5, -7) proPSA based artificial neural network to detect prostate cancer. *Eur Urol* 2006;50:1014-20
- Recker F. Prostate specific antigen in individual cancer checkups and in therapeutic treatment. *Ther Umsch* 2006;63:135-41

2005

- Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA, Jung K. A multicenter clinical trial on the use of (-5, -7) pro PSA. *J Urol.* 2005;174:2150-2153
- Recker F. Wann ist eine PSA-Bestimmung sinnvoll? *Primary Care* 2005;5:328-329
- Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Jung K. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. *Clin Chem.* 2005;51:532-9

2004

- Kwiatkowski M, Huber A, Moschopoulos M, Lehmann K, Wernli M, Häfeli A, Recker F. Screening for prostate cancer. Results of a prospective trial in Canton Aargau, Switzerland. *Swiss Med Wkly* 2004;134:580–585
- Recker F, Kwiatkowski M. PSA-Screening for prostate cancer - yes or no? *Ther Umschau* 2004;61:353-8
- Recker F, Kwiatkowski M. Prostatakrebs: Wo steht die Vorsorge im Jahr 2004? *Schweiz Med Forum* 2004;4:509–512

2003

- Heiss P, Kwiatkowski M, Lenz H, Pettersson K, Recker F, Hösel W, Eckert B. Human glandular kallikrein 2 and [-7]proPSA can improve the specificity of prostate



- cancer within PSA range 2-4 ng/ml. *Anticancer Research*, 23 (6B): V1, 2003
- Zusammenarbeit bei der Herausgabe des Supplements: The European Randomised Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994-2003. *BJU Int.* 2003, 92 (Suppl.2).
 - Schroder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, Villers A, Rebillard X, Ciatto S, Zappa M, Berenguer A, Paez A, Hugosson J, Lodding P, Recker F, Kwiatkowski M, Kirkels WJ; ERSPC. The story of the European Randomized Study of Screening for Prostate Cancer. *BJU Int.* 2003 Dec;92 Suppl 2:1-13.
 - Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Häfeli A, Recker F. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. *BJU Int.* 2003;92 (Suppl.2):44-47
 - Lein M, Kwiatkowski M, Semjonow A, Luboldt H-J, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening S, Jung K: A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. *J Urol* 2003;170:1175-1179

2001

- Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. *J Urol* 166:851-5, 2001
- Recker F. Vorsorgeuntersuchung und diagnostischer Algorithmus. In: Prostatakrebs. Fakten und Handlungsbedarf. Nationales Krebs-Bekämpfungsprogramm, S. 24-26. Hrsg. Bundesamt für Gesundheit und Krebsliga Schweiz.

2000

- Recker F, Lummen G: Prostatic carcinoma. Screening--when and what?. *Ther Umsch* 57: 33-7, 2000
- Recker F, Kwiatkowski M, Piironen T, Pettersson K, Huber A, Lummen G, Tscholl R. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. *Urology* 55: 481-5, 2000



1999

- Recker F, Kwiatkowski M, Piironen T, Otto T, Tscholl R. Korrelationen von human glandulärem Kallikrein mit freiem, total und an alpha 1 Antichymotrypsin gebundenem PSA bei unterschiedlichen Prostataerkrankungen 160-164. In: Urologie im Wandel Hrsg.Jonas 1999, Biermann Verlag,160-164

1998

- Recker F, Kwiatkowski M.K, Piironen T, Pettersson K, Lummen G, Wernli M, Wiefelsputz J, Graber S.F, Huber A, Tscholl R. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. *Cancer* 1998;83:2540-2547
- Kwiatkowski M.K, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/ml. *Urology* 1998;52:360-365
- Recker F, Kwiatkowski M.K, Piironen T. Improving the specificity of PSA's in the diagnostic gray zone 4-10 ng/ml by human glandular kallikrein. *Urologe A* 1998;37:421-423
- Recker F, Kwiatkowski M.K, Piironen T, Pettersson K, Goepel M, Tscholl R. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels. *Br J Urol* 81:532, 1998
- Recker F, Kwiatkowski M.K, Pettersson K, Piironen T, Lummen G, Huber A, Tscholl R. Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia. *Eur Urol* 1998;33:549-55

1997

- Recker F, Kwiatkowski M, Pettersson K, Piironen T, Reisto T, Tscholl R. Serum expression of different prostate specific antigen forms in different zones of the prostate. *Urological Research* 25:96, 1997



1996

- Recker F. What influence has the introduction of the prostate-specific antigen on the diagnostic of organ-confined prostate cancer. *Urologe B*, 1996;36:266
- Recker F. Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma. *Schweiz Med Wochenschr* 1996;126:1881